此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Compressive Dressing and Pharyngocutaneous Fistula After Primary Total Laryngectomy (TIGHT)

2026年11月15日 更新者:Andrea Galli、IRCCS San Raffaele

Impact of Compressive Dressing on the Risk of Pharyngocutaneous Fistula After Primary Total Laryngectomy: A Multicenter Retrospective Observational Study

Pharyngocutaneous fistula (PCF) is one of the most feared complications after total laryngectomy. A compressive neck dressing is often applied after surgery to try to prevent it, but there is no consensus on whether it works or how long it should be kept, and practice varies widely between centers. This multicenter, retrospective, observational study compares the rate of PCF in adult patients with laryngeal squamous cell carcinoma who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa and who did or did not receive a postoperative compressive dressing. It also examines whether the duration of the dressing affects the risk of fistula and how fistulas were managed in the two groups. All data are collected from existing medical records; no additional treatment or examination is performed.

研究概览

详细说明

PCF occurs in about 14% of primary total laryngectomies and about 28% of salvage procedures. It is associated with prolonged hospital stay, higher costs, delayed adjuvant treatment, and further complications. No study has directly compared patients managed with and without a postoperative compressive dressing.

This is a non-profit, multicenter, national, retrospective observational study coordinated by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Consecutive patients who underwent primary total laryngectomy from January 1, 2014 to the study start date are included. All patients were treated according to routine clinical practice at each center. Patients are divided into two groups according to postoperative management: compressive dressing of the cervical region over the neopharyngeal suture (Group A) or no compressive dressing (Group B).

Data are extracted from medical records and entered in pseudonymized form in an electronic case report form (REDCap). Collected variables include demographics, smoking and alcohol use, comorbidities, preoperative laboratory values and inflammatory indices, tumor site and clinical stage, surgical details (neck dissection, thyroidectomy, pharyngeal closure technique, salivary stent, primary voice prosthesis), postoperative antibiotic protocol, time to oral feeding, and fistula characteristics and management.

The planned sample size is 950 patients (475 per group), which provides 80% power to detect a 6.0% difference in fistula rate between groups, assuming a baseline rate of 14.3% in the group without compressive dressing, using a two-sided Fisher's exact test with alpha 0.05. The primary outcome will be analyzed with Fisher's exact test. Secondary outcomes will be analyzed with logistic and linear regression. Confounding will be addressed with propensity score matching, inverse probability weighting, or covariate adjustment, as appropriate.

研究类型

观察性的

注册 (估计的)

950

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Bergamo、意大利
        • 招聘中
        • ASST Papa Giovanni XXIII
        • 接触:
      • Bologna、意大利
        • 招聘中
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
        • 接触:
          • Edoardo Serafini, Medical Degree
          • 电话号码:+39 051 2145263
      • Bologna、意大利
        • 招聘中
        • Ospedale Maggiore Carlo Alberto Pizzardi
        • 接触:
      • Bolzano、意大利
        • 招聘中
        • Ospedale Centrale di Bolzano
        • 接触:
          • Luca Calabrese, medical degree
          • 电话号码:+39 0471 438641
          • 邮箱:orlbz@sabes.it
      • Brescia、意大利
        • 招聘中
        • ASST degli Spedali Civili di Brescia
        • 接触:
      • Candiolo、意大利
        • 招聘中
        • IRCCS Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia
        • 接触:
      • Cesena、意大利
      • Florence、意大利
        • 招聘中
        • Azienda Ospedaliero-Universitaria Careggi
        • 接触:
          • Giandomenico Maggiore, Medical Degree
          • 电话号码:+39 055 7942000
      • Forlì、意大利
        • 招聘中
        • Ospedale G.B. Morgagni - L. Pierantoni
        • 接触:
      • Milan、意大利
      • Milan、意大利
      • Modena、意大利
        • 招聘中
        • Azienda Ospedaliero-Universitaria Policlinico di Modena
        • 接触:
      • Naples、意大利
      • Padova、意大利
        • 招聘中
        • Azienda Ospedale-Università di Padova
        • 接触:
      • Pavia、意大利
        • 招聘中
        • Fondazione IRCCS Policlinico San Matteo
        • 接触:
      • Pescara、意大利
      • Ravenna、意大利
      • Reggio Emilia、意大利
        • 招聘中
        • Arcispedale Santa Maria Nuova
        • 接触:
      • Rimini、意大利
      • Roma、意大利
      • Roma、意大利
      • Roma、意大利
      • Torino、意大利
        • 招聘中
        • AOU Città della Salute e della Scienza (Molinette)
        • 接触:
      • Trieste、意大利
        • 招聘中
        • Ospedale di Cattinara
        • 接触:
          • Giancarlo Tirelli, Medical Degree
          • 电话号码:+39 040 3994933
          • 邮箱:tirellig@units.it
      • Verona、意大利
        • 招聘中
        • Azienda Ospedaliera Universitaria Integrata di Verona
        • 接触:
      • Vittorio Veneto、意大利
        • 招聘中
        • Ospedale di Vittorio Veneto - ULSS 2 Marca Trevigiana
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Consecutive adult patients with squamous cell carcinoma of the larynx who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa at the participating Italian otolaryngology centers from January 1, 2014 to the study start date.

描述

Inclusion Criteria:

  • Squamous cell carcinoma of the larynx treated with primary total laryngectomy
  • Primary closure of the hypopharyngeal mucosa
  • Age 18 years or older
  • Informed consent to study participation and to personal data processing
  • Availability of data on comorbidities, laboratory parameters, and postoperative management

Exclusion Criteria:

  • Salvage total laryngectomy
  • Previous radiotherapy or chemoradiotherapy to the head and neck
  • Previous open surgery of the pharyngolaryngeal region
  • Reconstruction with a free or pedicled flap (inlay or onlay)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:RETROSPECTIVE

队列和干预

团体/队列
干预/治疗
Compressive dressing (Group A)

Patients who received a postoperative compressive dressing of the cervical region over the neopharyngeal suture after primary total laryngectomy, according to routine clinical practice at the treating center.

Postoperative compressive dressing applied to the cervical region over the neopharyngeal suture. This is an exposure observed in routine clinical practice; it is not assigned by the study.

No compressive dressing (Group B)

Patients who did not receive a postoperative compressive dressing after primary total laryngectomy, according to routine clinical practice at the treating center.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of pharyngocutaneous fistula
大体时间:During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients who develop a pharyngocutaneous fistula in each group (compressive dressing vs no compressive dressing).

During the postoperative hospital stay (from surgery to discharge), up to 60 days

次要结果测量

结果测量
措施说明
大体时间
Incidence of pharyngocutaneous fistula by duration of compressive dressing
大体时间:During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients in Group A who develop a pharyngocutaneous fistula, stratified by duration of the compressive dressing (days).

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to onset of pharyngocutaneous fistula
大体时间:During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from surgery to diagnosis of pharyngocutaneous fistula in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Type of management of pharyngocutaneous fistula
大体时间:During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients with fistula managed conservatively (compressive dressing) or surgically in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Resolution of pharyngocutaneous fistula
大体时间:During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients whose fistula resolved, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to resolution of pharyngocutaneous fistula
大体时间:During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from diagnosis to resolution of the fistula, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Edoardo Serafini, Medical Degree、IRCCS Azienda Ospedaliero-Universitaria di Bologna

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月5日

初级完成 (估计的)

2027年1月5日

研究完成 (估计的)

2027年3月31日

研究注册日期

首次提交

2026年11月15日

首先提交符合 QC 标准的

2026年11月15日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月15日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data underlying the published results will be made available upon reasonable request to the Principal Investigator.

IPD 共享时间框架

After publication of the study results in a peer-reviewed journal.

IPD 共享访问标准

Data will be shared with researchers who submit a motivated request to the Principal Investigator of the coordinating center (IRCCS Azienda Ospedaliero-Universitaria di Bologna).

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅